- Home
- BXC vs PRTA Comparison
BXC vs PRTA Comparison
Compare BXC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- PRTA
- Stock Information
- Founded
- BXC 2004
- PRTA 2012
- Country
- BXC United States
- PRTA Ireland
- Employees
- BXC N/A
- PRTA N/A
- Industry
- BXC Wholesale Distributors
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BXC Consumer Discretionary
- PRTA Health Care
- Exchange
- BXC Nasdaq
- PRTA Nasdaq
- Market Cap
- BXC 869.2M
- PRTA 765.2M
- IPO Year
- BXC 2004
- PRTA N/A
- Fundamental
- Price
- BXC $82.41
- PRTA $15.56
- Analyst Decision
- BXC Strong Buy
- PRTA Buy
- Analyst Count
- BXC 4
- PRTA 8
- Target Price
- BXC $127.75
- PRTA $46.00
- AVG Volume (30 Days)
- BXC 70.3K
- PRTA 336.3K
- Earning Date
- BXC 02-18-2025
- PRTA 02-20-2025
- Dividend Yield
- BXC N/A
- PRTA N/A
- EPS Growth
- BXC 14.84
- PRTA N/A
- EPS
- BXC 6.19
- PRTA N/A
- Revenue
- BXC $2,952,532,000.00
- PRTA $135,157,000.00
- Revenue This Year
- BXC N/A
- PRTA $56.89
- Revenue Next Year
- BXC $4.41
- PRTA N/A
- P/E Ratio
- BXC $13.33
- PRTA N/A
- Revenue Growth
- BXC N/A
- PRTA 47.92
- 52 Week Low
- BXC $82.23
- PRTA $11.70
- 52 Week High
- BXC $134.79
- PRTA $31.03
- Technical
- Relative Strength Index (RSI)
- BXC 22.63
- PRTA 59.65
- Support Level
- BXC $86.21
- PRTA $13.69
- Resistance Level
- BXC $103.10
- PRTA $15.09
- Average True Range (ATR)
- BXC 3.66
- PRTA 0.91
- MACD
- BXC -1.99
- PRTA 0.13
- Stochastic Oscillator
- BXC 0.69
- PRTA 68.56
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).